Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Peptides
; 176: 171219, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38615717
ABSTRACT
People with obesity and type 2 diabetes have a high prevalence of metabolic-associated steatotic liver disease, hyperlipidemia and cardiovascular disease. Glucagon increases hepatic glucose production; it also decreases hepatic fat accumulation, improves lipidemia and increases energy expenditure. Pharmaceutical strategies to antagonize the glucagon receptor improve glycemic outcomes in people with diabetes and obesity, but they increase hepatic steatosis and worsen dyslipidemia. Co-agonism of the glucagon and glucagon-like peptide-1 (GLP-1) receptors has emerged as a promising strategy to improve glycemia in people with diabetes and obesity. Addition of glucagon receptor agonism enhances weight loss, reduces liver fat and ameliorates dyslipidemia. Prior to clinical use, however, further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists in people with diabetes and obesity and related conditions, with specific concerns regarding a higher prevalence of gastrointestinal side effects, loss of muscle mass and increases in heart rate. Furthermore, co-agonists with differing ratios of glucagonGLP-1 receptor activity vary in their clinical effect; the optimum balance is yet to be identified.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Glucagón
/
Diabetes Mellitus Tipo 2
/
Receptor del Péptido 1 Similar al Glucagón
/
Obesidad
Límite:
Humans
Idioma:
En
Revista:
Peptides
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos